Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wouter W de Herder

Showing results (51-60 of 238) with videos related to

Pageof 24
Sort By:
Neuroendocrinology|January 30, 2020
Importance of Complete Pathology Reporting for Neuroendocrine Carcinoma: WHO Guidelines Are a Good Start but Not EnoughWouter T Zandee, Jan Maarten van der Zwan, Wouter W de Herder, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 9, 2022
Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor PatientsNoémie S Minczeles, Wouter W de Herder, Richard A Feelders, et al.
Clinical Nuclear Medicine|April 15, 2022
Dose-Limiting Bone Marrow Toxicities After Peptide Receptor Radionuclide Therapy Are More Prevalent in Women Than in MenNoémie S Minczeles, Wouter W de Herder, Mark W Konijnenberg, et al.
European Journal of Endocrinology|August 6, 2016
Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumoursWouter T Zandee, Kimberly Kamp, Roxanne C S van Adrichem, et al.
European Journal of Pediatrics|May 10, 2002
Congenital hemihypertrophy and pheochromocytoma, not a coincidental combination?Erica L T van den Akker, Ronald R de Krijger, Wouter W de Herder, et al.
Neuroendocrinology|January 5, 2006
Octreotide exerts only acute, but no sustained, effects on MRI enhancement of liver metastases in carcinoid syndromeMenno T Zomerhuis, Shahid M Hussain, Richard A Feelders, et al.
Pituitary|January 12, 2011
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patientsSebastian J C M M Neggers, Wouter W de Herder, Richard A Feelders, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|August 12, 2003
Amiodarone therapy before heart transplantation as a predictor of thyroid dysfunction after transplantationReinold Siccama, Aggie H M M Balk, Wouter W de Herder, et al.
Neuroendocrinology|August 29, 2009
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogsDik J Kwekkeboom, Eric P Krenning, Rachida Lebtahi, et al.
The Journal of Clinical Endocrinology and Metabolism|May 4, 2021
Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid SyndromeWouter T Zandee, Tessa Brabander, Anela Blažević, et al.
Pageof 24

Showing results (51-60 of 238) with videos related to

Sort By:
Pageof 24
Neuroendocrinology|January 30, 2020
Importance of Complete Pathology Reporting for Neuroendocrine Carcinoma: WHO Guidelines Are a Good Start but Not EnoughWouter T Zandee, Jan Maarten van der Zwan, Wouter W de Herder, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 9, 2022
Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor PatientsNoémie S Minczeles, Wouter W de Herder, Richard A Feelders, et al.
Clinical Nuclear Medicine|April 15, 2022
Dose-Limiting Bone Marrow Toxicities After Peptide Receptor Radionuclide Therapy Are More Prevalent in Women Than in MenNoémie S Minczeles, Wouter W de Herder, Mark W Konijnenberg, et al.
European Journal of Endocrinology|August 6, 2016
Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumoursWouter T Zandee, Kimberly Kamp, Roxanne C S van Adrichem, et al.
European Journal of Pediatrics|May 10, 2002
Congenital hemihypertrophy and pheochromocytoma, not a coincidental combination?Erica L T van den Akker, Ronald R de Krijger, Wouter W de Herder, et al.
Neuroendocrinology|January 5, 2006
Octreotide exerts only acute, but no sustained, effects on MRI enhancement of liver metastases in carcinoid syndromeMenno T Zomerhuis, Shahid M Hussain, Richard A Feelders, et al.
Pituitary|January 12, 2011
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patientsSebastian J C M M Neggers, Wouter W de Herder, Richard A Feelders, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|August 12, 2003
Amiodarone therapy before heart transplantation as a predictor of thyroid dysfunction after transplantationReinold Siccama, Aggie H M M Balk, Wouter W de Herder, et al.
Neuroendocrinology|August 29, 2009
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogsDik J Kwekkeboom, Eric P Krenning, Rachida Lebtahi, et al.
The Journal of Clinical Endocrinology and Metabolism|May 4, 2021
Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid SyndromeWouter T Zandee, Tessa Brabander, Anela Blažević, et al.
Pageof 24